CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1

2016 ◽  
Vol 85 (1) ◽  
pp. 103-112 ◽  
Author(s):  
M. Gavanier ◽  
A. Ayav ◽  
C. Sellal ◽  
X. Orry ◽  
M. Claudon ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Solid Tumor ◽  
European Association ◽  
Evaluation Criteria ◽  
Advanced Hepatocellular Carcinoma ◽  
Imaging Findings ◽  
Response Evaluation ◽  
Alternative Response ◽  
Recist 1.1 ◽  
Response Evaluation Criteria

The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST

2018 ◽  
Vol 104 (2) ◽  
pp. 88-95 ◽  
Author(s):  
Alessandro Inno ◽  
Giuseppe Lo Russo ◽  
Matteo Salgarello ◽  
Giulia Corrao ◽  
Raffaella Casolino ◽  
...  
Keyword(s):  
Tumor Response ◽  
Objective Response ◽  
Evaluation Criteria ◽  
Therapy Response ◽  
Clinical Activity ◽  
Special Focus ◽  
Response Evaluation ◽  
Recist 1.1 ◽  
New Anticancer Drugs ◽  
Response Evaluation Criteria

The objective response is an important endpoint to evaluate clinical activity of new anticancer drugs. Standardized criteria for evaluating response are needed for comparing results of different trials and represent the basis for advances in cancer therapy. Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 are the most used in clinical practice and in clinical trials; however, they are not able to capture atypical responses seen with immunotherapy drugs. We describe the evolution of response criteria with a special focus on the immune-related criteria.

Sign in / Sign up

Export Citation Format

Share Document